Fulcrum Therapeutics (FULC) PT Lowered to $14 at Oppenheimer
Tweet
Share
E-mailGet Alerts FULC Hot Sheet
Price: $3.87 +0.78%
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Oppenheimer analyst Matthew Biegler lowered the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $14.00 (from $16.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Amgen (AMGN) PT Raised to $400 at Cantor Fitzgerald on Higher Sales Estimates
- Duos Technologies Group (DUOT) PT Raised to $27 at Cantor Fitzgerald on 'Extremely Attractive' Risk/Reward
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
